Amgen

Open: 280.0 Close: 284.16 Change: 4.16

What an AI can tell you about Amgen Company Inc before investing.

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, stock, data, dividend, share, current, New, and the …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen announced a $650 million write-down after discontinuing AMG 340, a prostate cancer candidate acquired in the $900 million buy of Tenobio in 2021. Amgen is slated to publish early stage trial data on an oral weight loss medication.

Today's News

New drug data from Pfizer and Amgen could alter the markets competitive landscape in the coming months. Amgen is slated to publish early stage trial data on an oral weight loss medication in the first half of 2024. In the second half of the year, Amgen plans to release mid-stage trial data. Amgen raises quarterly dividend by 5.6% to $2.25/share. FDA grants priority review to Amgens Tarlatamab Application for Advanced Small Cell Lung Cancer. Amgen Axes Prostate Cancer Drug, Takes $650M Write-Down as Q3 Profit Drops 10/31/2023 In its third-quarter results Tuesday, Amgen announced a $650 million write-down after discontinuing AMG 340, a prostate cancer candidate acquired in the $900 million buy of Tenobio in 2021. Amgen is expected to post earnings of $4.69 per share for the current quarter. The expected new shipment finally caucuses euph dungeon Horizon Therapeutics (HZNP) stock is sinking after the FTC reportedly decided to sue to block its merger with Amgen (AMGN) 7 Blue-Chip Stocks to Buy in May. Amgen stock added 1.4% after BMO Capital Markets upgraded the biopharma firm to an outperform rating. Scam Advisory: Special Advisory: Please be cautious of scam recruitment offers. Amgen shares rise as analysts see ‘value obesity play - marketwatch.com. The developing pipeline “gives investors the opportunity to play in the obesity metabolic space without the same premium as peers,” BMO analyst Evan David Seigerman wrote in a research note. Amgen announced that its Board of Directors declared a $2.25 per share dividend for the first quarter of 2024. Thats the 12th straight year that Amgen has increased its dividend. Amgen stock price | amgn stock quote, news, and history | markets insider. New: Online Broker Comparison. Shares of Amgen topped the list of the days best performing Dow Jones Industrial Average components, trading up 1.2%. Year to date, Amgen registers a 7.7% gain. Amgen stock has amassed a healthy 18.3% lead over the past nine months. The number of employees of the company Amgen headquartered in the United States remained nearly unchanged at around 24.2. Amgen Ventures invests in early-stage biotechnology companies focused on discovering and developing human therapeutics. The fund, which focuses primarily on areas of current therapeutic interest to Amgen. Amgen Ventures partners with University of California Berkeley on May 5, 2015. Amgen has 1 team member, including current Senior Vice President, Rachna Khosla.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, stock, data, dividend, share, current, New, and the most common words in the summary are: amgen, market, stock, inc, best, news, development, . One of the sentences in the summary was: Amgen announced a $650 million write-down after discontinuing AMG 340, a prostate cancer candidate acquired in the $900 million buy of Tenobio in 2021. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #market #stock #inc #best #news #development.